Studies on the Activity of Selected Highly Lipophilic Compounds toward hGAT1 Inhibition. Part II

ACS Chem Neurosci. 2019 Jan 16;10(1):337-347. doi: 10.1021/acschemneuro.8b00282. Epub 2018 Sep 28.

Abstract

In this paper, we describe the latest results involving molecular modeling and pharmacodynamic studies of the selected highly lipophilic compounds acting by human GABA transporter 1 (hGAT1) inhibition. The chemical interaction of 17 GABA analogues with a model of hGAT1 is described using the molecular docking method. The biological role of GAT1 is related to the regulation of GABA level in the central nervous system and GAT1 inhibition plays an important role in the control of seizure threshold. To confirm that GAT1 can be also a molecular target for drugs used to treat other neurological and psychiatric diseases (e.g., pain and anxiety), in the in vivo part of this study, potential antinociceptive and anxiolytic-like properties of tiagabine, a selective GAT1 inhibitor, are described.

Keywords: GABA; Molecular docking; antiepileptic drugs; hGAT1; mice; neurogenic pain; obsessive-compulsive disorder.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anxiety / drug therapy
  • Anxiety / psychology
  • GABA Plasma Membrane Transport Proteins / metabolism*
  • GABA Uptake Inhibitors / administration & dosage*
  • GABA Uptake Inhibitors / chemistry
  • Humans
  • Lipids / administration & dosage*
  • Male
  • Mice
  • Molecular Docking Simulation / methods*
  • Pain Measurement / drug effects
  • Pain Measurement / methods
  • Structure-Activity Relationship
  • Tiagabine / administration & dosage
  • Tiagabine / chemistry

Substances

  • GABA Plasma Membrane Transport Proteins
  • GABA Uptake Inhibitors
  • Lipids
  • SLC6A1 protein, human
  • Tiagabine